carbetocin
Trade name: Pabal
Carbetocin, sold under the brand names Pabal among others, is a medication used to prevent excessive bleeding after childbirth, particularly following Cesarean section. It appears to work as well as oxytocin. Due to it being less economical than other options, use is not recommended by NHS Scotland. It is given by injection into a vein or muscle. — Wikipedia
Clinical trial activity
79 trials · 60 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2006 (NCT00499005)
Timeline
Indications
Approved for
Studied for
- Anemia · Phase 4
- Anesthesia · Phase 4
- Arrhythmias, Cardiac · Phase 4
- Blood Loss, Surgical · Phase 4
- Bronchiectasis · Phase 4
- Cardiovascular Diseases · Phase 4
- Cesarean Section · Phase 4
- Delivery, Obstetric · Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drug Therapy · Phase 4
- Hemodynamics · Phase 4
- Hemorrhage · Phase 4
- Hypersensitivity · Phase 4
- Leiomyoma · Phase 1
- Myocardial Ischemia · Phase 4
- Myoma · Phase 4
- Obstetrics · Phase 3
- Pharmacokinetics · Phase 4
- Postpartum Hemorrhage · Phase 4
- Prader-Willi Syndrome · Phase 3
- Pre-Eclampsia · Phase 3
- Pregnancy · Phase 4
- Pregnancy Complications · Phase 4
- Pregnancy, High-Risk · Early Phase 1
- Pregnancy in Obesity · Phase 1/Phase 2
- Primary Prevention · Phase 4
- Uterine Inertia · Phase 4
- Uterine Myomectomy · Phase 4
Mechanism of action
- Oxytocin receptorAGONIST
OXTR agonist
Carbetocin is a long-acting synthetic octapeptide analogue of oxytocin with agonist properties. Like oxytocin, carbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions and increased uterine tone.
Chemistry & pharmacology
SMILES
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O- Mol. weight
- 988.18 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCarbetocin ↗
- ChEMBLCHEMBL3301668 ↗
Also known as
- 1-butanoic acid-2-(o-methyl-l-tyrosine)-1-carbaoxytocin
- 1-butyric acid-2-(3-(p-methoxyphenyl)-l-alanine)oxytocin
- 1-butyric acid-2-(3-(p-methoxyphenyl)-l-alanine)oxytocin
- 1-carbaoxytocin, 1-butanoic acid-2-(o-methyl-l-tyrosine)-
- 1-deamino-1-monocarba-2-(tyr(ome))-oxytocin
- carbetocin
- carbetocin
- carbetocin
- carbetocin
- carbetocin
- carbetocin
- carbetocin
- carbetocin
- carbetocino
- carbetocino
- carbetocinum
- carbetocinum
- dcomot
- deamino-2-o-methyltyrosine-1-carbaoxytocin
- depotocin
- depotocin
- duratocin
- duratocin
- duratocin
- fe 992097
- oxytocin, 1-desamino-1-monocarba-(tyr(ome))(2)-
- oxytocin, 1-desamino-1-monocarba-(tyrosine(o-methyl))(2)-
- pabal
- pabal
- pabal
- pabal
- pabal
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07187544 | N/A | Sep 30, 2025 | Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Canada |
| NCT06930391 | N/A | Sep 15, 2025 | Icahn School of Medicine at Mount Sinai |
| NCT06946589 | Phase 4 | Aug 1, 2025 | Queen's University, Belfast |
| NCT06333340 | N/A | Oct 31, 2024 | Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Canada |
| NCT06285409 | N/A | Apr 4, 2024 | Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Canada |
| NCT06420297 | Phase 3 | Mar 11, 2024 | Acadia Pharmaceuticals |
| NCT06173531 | Phase 3 | Nov 27, 2023 | Acadia Pharmaceuticals |
| NCT06217354 | Phase 1/Phase 2 (Phase 2) | Jul 6, 2023 | Cairo University |
| NCT05924321 | Phase 1 | May 25, 2023 | Ferring |
| NCT05806307 | Phase 4 | Mar 15, 2023 | Cairo University |
| NCT05742854 | Phase 4 | Mar 9, 2023 | Ege University |
| NCT05986266 | Phase 1 | Feb 1, 2023 | Cairo University |
| NCT05664659 | Phase 4 | Dec 31, 2022 | Ain Shams University |
| NCT05467462 | N/A | Aug 1, 2022 | Bezmialem University |
| NCT05479357 | N/A | Jul 28, 2022 | Sohag University |
| NCT05266534 | N/A | Dec 30, 2021 | Wael El-Banna Clinic Cairo Egypt |
| NCT05110482 | Phase 4 | Nov 30, 2021 | Cairo University |
| NCT04902729 | N/A | Jul 20, 2021 | Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Canada |
| NCT04595812 | Phase 4 | Nov 1, 2020 | Cairo University |
| NCT04482959 | Phase 4 | Jul 15, 2020 | Mansoura University |
Organizations
Research & Development (60)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cairo University | Academic/Hospital | 16 | 13 | 4 | 2011 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 14 | 14 | 1 | 2010 |
| Aswan University | Academic/Hospital | 6 | 6 | 1 | 2018 |
| Mount Sinai Hospital, Canada | Academic/Hospital | 6 | 0 | 1 | 2018 |
| Ain Shams University | Academic/Hospital | 5 | 4 | 2 | 2012 |
| Beni Suef University | Academic/Hospital | 3 | 3 | 1 | 2014 |
| Ferring | For profit | 3 | 2 | 3 | 2014 |
| University of Bern | Academic/Hospital | 3 | 3 | 2 | 2013 |
| Acadia Pharmaceuticals | For profit | 2 | 2 | 1 | 2023 |
| Assiut University | Academic/Hospital | 2 | 1 | 1 | 2012 |
| Osaka University | Academic/Hospital | 2 | 2 | 1 | 2009 |
| Sohag University | Academic/Hospital | 2 | 2 | 1 | 2012 |
| University of British Columbia | Academic/Hospital | 2 | 2 | 1 | 2016 |
| University of Oslo | Academic/Hospital | 2 | 1 | 1 | 2015 |
| Al Azhar University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Al- Elweyia Maternity Teaching Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| assistant profossor | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Bangladesh Medical University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Benha University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Bezmialem University | Academic/Hospital | 1 | 1 | 1 | 2022 |